You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

ISTH, Kedrion supports symposium on the importance of inhibitor eradication

The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A

read more 

EVENTS

Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020

The company reaffirms its commitment to the patient community during the COVID-19 epidemic

read more 

CORPORATE

Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel

The two companies are now working to expand the Clinical Development Program to the US

read more 
  1. EVENTS - 26-07-2016

    SIPPET Study was WHF 2016 World Congress highlight

    A Kedrion, Grifols and LFB supported symposium featured a lecture by Dr. Manuel Carcao

    read more 
  2. CORPORATE - 17-06-2016

    Kedrion Biopharma consolidates presence on Russian market

    Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant

    read more 
  3. CORPORATE - 26-05-2016

    SIPPET study results published in the “New England Journal of Medicine”

    This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world

    read more 
  4. CORPORATE - 06-05-2016

    Kedrion Biopharma for Mother's Day

    We are committed to helping eliminate Rh disease worldwide by supporting initiatives like CURhE

    read more 

Pages

For more information please contact: pressoffice@kedrion.com